Cargando…

Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma

Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yixing, Liu, Bao, Feng, Lan, Sun, Binda, He, Shu, Yang, Yidong, Wu, Gang, E, Guoji, Liu, Chang, Gao, Yuqi, Zhang, Erlong, Zhu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367651/ https://www.ncbi.nlm.nih.gov/pubmed/30775317 http://dx.doi.org/10.3389/fonc.2019.00033

Ejemplares similares

Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
por: Gao, Yixing, et al.
Publicado: (2020)

Integrated analysis identified core signal pathways and hypoxic characteristics of human glioblastoma
por: Gao, Yixing, et al.
Publicado: (2019)

Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways
por: Li, Hailong, et al.
Publicado: (2022)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

IL-10 Dysregulation in Acute Mountain Sickness Revealed by Transcriptome Analysis
por: Liu, Bao, et al.
Publicado: (2017)

Escape From Cisplatin-Induced Senescence of Hypoxic Lung Cancer Cells Can Be Overcome by Hydroxychloroquine
por: Olszewska, Aleksandra, et al.
Publicado: (2022)

Prospective signs of cleidocranial dysplasia in Cebpb deficiency
por: Huang, Boyen, et al.
Publicado: (2014)

CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma
por: Yang, Jingrun, et al.
Publicado: (2022)

Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival
por: Burgess, Eleanor R., et al.
Publicado: (2022)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis
por: Gao, Yixing, et al.
Publicado: (2022)

The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response
por: Crake, Rebekah L. I., et al.
Publicado: (2021)

Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis
por: Zhou, Zili, et al.
Publicado: (2022)

Microarray data analysis to identify crucial genes regulated by CEBPB in human SNB19 glioma cells
por: Du, Chenghua, et al.
Publicado: (2016)

Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
por: Takei, Jun, et al.
Publicado: (2022)

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1
por: Cai, Shijiao, et al.
Publicado: (2020)

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
por: Tang, Lin, et al.
Publicado: (2021)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
por: Wu, Donglu, et al.
Publicado: (2020)

Transcription Factor CEBPB Inhibits the Expression of the Human HTR1A by Binding to 5′ Regulatory Region In Vitro
por: Liu, Yong-Ping, et al.
Publicado: (2019)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

Changes in CEBPB expression in circulating leukocytes following eccentric elbow-flexion exercise
por: Blackwell, Jamie, et al.
Publicado: (2014)

Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling
por: Wang, Xiaoyang, et al.
Publicado: (2022)

Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A
por: Lu, Jianhua, et al.
Publicado: (2019)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Hypoxic Signalling in Tumour Stroma
por: Laitala, Anu, et al.
Publicado: (2018)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

HDAC-an important target for improving tumor radiotherapy resistance
por: Ling, Rui, et al.
Publicado: (2023)

Targeting hypoxic tumour cells to overcome metastasis
por: Bennewith, Kevin L, et al.
Publicado: (2011)

Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?
por: Wang, Hui, et al.
Publicado: (2019)

Loss of Stemness, EMT, and Supernumerary Tooth Formation in Cebpb(−/−)Runx2(+/−) Murine Incisors
por: Saito, Kazuyuki, et al.
Publicado: (2018)

Insights Into the Function and Clinical Application of HDAC5 in Cancer Management
por: Yang, Jun, et al.
Publicado: (2021)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

Rapid progression of subcutaneous glioblastoma: A case report and literature review
por: Wang, Fang, et al.
Publicado: (2023)

Hypoxic stress and hypoxia-inducible factors in leukemias
por: Magliulo, Daniela, et al.
Publicado: (2022)

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma
por: Lee, Dae-Hee, et al.
Publicado: (2015)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells
por: Fu, Wanbin, et al.
Publicado: (2022)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fgoq50d0oqoj0kk4ja2keq8shs